ROYSTON IVOR 4
4 · Viracta Therapeutics, Inc. · Filed May 26, 2023
Insider Transaction Report
Form 4
ROYSTON IVOR
DirectorCEO & President
Transactions
- Exercise/Conversion
Common Stock
2023-05-25+25,219→ 688,427 total - Exercise/Conversion
Restricted Stock Units
2023-05-25−25,219→ 201,752 total→ Common Stock (25,219 underlying)
Holdings
- 18,599(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
- [F2]One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.